|An evaluation of epidemiological and reporting characteristics of complementary and alternative medicine (CAM) systematic reviews (SRs).|
|Jump to Full Text|
|PMID: 23341949 Owner: NLM Status: MEDLINE|
|BACKGROUND: Systematic reviews (SRs) are abundant. The optimal reporting of SRs is critical to enable clinicians to use their findings to make informed treatment decisions. Complementary and alternative medicine (CAM) therapies are widely used therefore it is critical that conduct and reporting of systematic research in this field be of high quality. Here, methodological and reporting characteristics of a sample of CAM-related SRs and a sample of control SRs are evaluated and compared.
METHODS: MEDLINE(®) was searched to identify non-Cochrane SRs indexed from January 2010 to May 2011. Control SRs were retrieved and a search filter was used to identify CAM SRs. Citations were screened and publications that met a pre-specified definition of a SR were included. Pre-designed, standardized data extraction forms were developed to capture reporting and methodological characteristics of the included reviews. Where appropriate, samples were compared descriptively.
RESULTS: A total of 349 SRs were identified, of which 174 were CAM-related SRs and 175 were conventional SRs. We compared 131 CAM-related non-Cochrane SRs to the 175 conventional non-Cochrane reviews. Fifty-seven percent (75/131) of CAM SRs specified a primary outcome compared to 21% (37/175) of conventional sample reviews. Reporting of publication bias occurred in less than 5% (6/131) of the CAM sample versus 46% (80/175) of the conventional sample of SRs. Source of funding was frequently and consistently under-reported. Less than 5% (11/306) of all SRs reported public availability of a review protocol.
CONCLUSION: The two samples of reviews exhibited different strengths and weaknesses. In some cases there were consistencies across items which indicate the need for continued improvements in reporting for all SR reports. We advise authors to utilise the PRISMA Statement or other SR guidance when reporting SRs.
|Lucy Turner; James Galipeau; Chantelle Garritty; Eric Manheimer; L Susan Wieland; Fatemeh Yazdi; David Moher|
Related Documents :
|19033709 - Recurrent hemifacial spasm following minor trauma: report of a case.
23640659 - Strategies to improve adverse drug reaction reporting: a critical and systematic review.
24696739 - Tumor rupture as an initial manifestation of malignant mesonephric mixed tumor: a case ...
24411929 - Thoracic pulmonary endometriosis: two reports of a rare disease.
23217489 - Pseudotumour of spleen.
24898789 - Critical review of the epidemiologic literature regarding the association between conge...
9689989 - Clinical characteristics associated with dup17(q24q25.1) in a mosaic mother and two non...
21490179 - Complications of the weil osteotomy.
7825559 - Coin-rubbing injuries.
|Type: Journal Article; Research Support, N.I.H., Extramural Date: 2013-01-14|
|Title: PloS one Volume: 8 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2013|
|Created Date: 2013-01-23 Completed Date: 2013-07-09 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e53536 Citation Subset: IM|
|Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Clinical Trials as Topic
Complementary Therapies / statistics & numerical data*
Meta-Analysis as Topic
Review Literature as Topic*
|R24 AT001293/AT/NCCAM NIH HHS; R24 AT001293-04/AT/NCCAM NIH HHS|
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Publisher: Public Library of Science, San Francisco, USA
Copyright: 2013 Turner et al
Received Day: 19 Month: 7 Year: 2012
Accepted Day: 3 Month: 12 Year: 2012
collection publication date: Year: 2013
Electronic publication date: Day: 14 Month: 1 Year: 2013
Volume: 8 Issue: 1
E-location ID: e53536
PubMed Id: 23341949
Publisher Id: PONE-D-12-21820
|An Evaluation of Epidemiological and Reporting Characteristics of Complementary and Alternative Medicine (CAM) Systematic Reviews (SRs) Alternate Title:Epi of CAM SRs|
|L. Susan Wieland2|
|William C. S. Choedit1||
1Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada
2Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
3Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
|Queen Elizabeth Hospital, Hong Kong
|Correspondence: * E-mail: email@example.com
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived of the project: DM. Designed the evaluation: DM LT. Reviewed and collected data for the project: JG CG LT. Contributed to the final version of the evaluation manuscript: LT JG CG EM LSW FY DM. Analyzed the data: LT FY. Wrote the paper: LT.
Systematic reviews (SRs) are a prominent and established component of evidence-based health care. On average, 11 new reviews are published daily . As with all research, the value of a SR depends on how it was conducted and reported. The reporting quality of SRs varies , limiting readers’ ability to assess the strengths and weaknesses of reviews . Poorly conducted and/or reported SRs may limit their usefulness for practice guideline developers and other stakeholders, such as policy makers.
In 2007, Moher et al. examined the epidemiological and reporting characteristics of a cross-section of 300 SRs indexed in MEDLINE® in November of 2004 . The authors noted: 40.7% of reviews did not report a source of funding; only 66.8% reported conducting some form of risk of bias assessment; and only 23.1% reported assessing publication bias. Just over half (53.7%) of evaluated reviews reported combining their results statistically, of which 91.3% assessed consistency across pooled studies. Only 17.7% were reported to be updates of SRs. No reviews reported a protocol registration number.
The prevalence of Complementary and Alternative Medicine (CAM) use in the general population is considerable . There are differences across surveys reporting global prevalence estimates of overall use of CAM which can be largely explained by different definitions of CAM within the various surveys. In 2000, a SR of surveys conducted to examine the prevalence of CAM use among general populations in countries worldwide found that a substantial proportion of the surveyed populations used CAM. However comparisons, both across countries and within countries, was difficult because of differences in definitions of CAM, differences in the reference time period for the use of these therapies, differences in study designs, and other methodological differences between surveys , . One recent estimate from a 2007 NIH survey suggests that 38.3% of American adults use some form of CAM . Regardless of the exact figure, the use of CAM treatments is prevalent in the general population. Therefore, it is critical that CAM research in this area, like all health research, adhere to high conduct and reporting standards in order to enable knowledge users to interpret report findings with confidence.
Information regarding deficiencies in the quality or reporting of specific aspects of SRs enables researchers to target methodological aspects of review conduct and reporting that can be improved with the aim of producing higher quality research. This report therefore evaluates and compares the methodological and reporting characteristics of two cross sectional MEDLINE® samples of SRs; CAM specific SRs and a sample of SRs across a variety of clinical topics. We also draw comparisons with the Moher 2007 paper  from which this evaluation was methodologically derived.
Two cross sectional samples of SRs published outside of the Cochrane Library have been evaluated. The first was comprised of SRs indexed from January 2010 to May 2011 pertaining to Complementary and Alternative Medicine, henceforth referred to as “CAM”, as defined, categorized and operationalized by the Cochrane CAM Field . The second sample, over the same time period, consisted of a cross sectional sample of SRs published in core clinical journals , henceforth referred to as “control”.
To be eligible for inclusion, articles for both samples had to meet the following definition of a SR , : search at least one database; provide a description of at least one eligibility criterion; and report the critical appraisal of included studies (Figure 1). Any type of SR was eligible (e.g., comparative effectiveness, prognostic, diagnostic), overviews of SRs were not eligible for inclusion. Unpublished SRs, including grey literature, were not included and SRs were not restricted by language of publication.
We conducted two independent electronic searches to identify both samples. For the CAM sample, we searched MEDLINE® via Ovid using an unpublished filter iteratively developed by a group of information specialists on behalf of the Canadian Agency for Drug and Technologies in Health . We then conducted the same search of MEDLINE® via Ovid, without filtering for CAM SRs, to identify control SRs [Appendix S1]. Due to the volume of literature, the search was limited to identify reports of SRs indexed between January 2010 and May 2011, inclusive. The search for the control sample was limited to core clinical journals .
Retrieved citations were screened based on inclusion criteria for a SR using online review software, DistillerSR® . Title and abstract screening was conducted by liberal acceleration (i.e., two reviewers needed to independently exclude a record; only one reviewer needed to include a record) and subsequent full text articles were retrieved and screened independently by two of four reviewers. Any disagreements were discussed and remaining conflicts were resolved by third party consensus. When full text screening of both samples was complete, a random sample of control SRs was generated by SAS, Version 9.1 , matching the total number of eligible CAM SRs. Translators, trained in epidemiology or biostatistics, assessed the eligibility of the non-English language studies identified.
Data were collected for both samples using a standardized form of 49 questions (available upon request). Items for data collection were determined a priori based on the Moher 2007 items . Pilot testing of the data extraction form was conducted to ensure consistency. Data extraction was completed and a 10% random sample of SRs was extracted independently in duplicate to assess accuracy within both samples. Extractors discussed and resolved all disagreements in order to achieve consensus.
Data were collected regarding three review components: epidemiological, descriptive and reporting characteristics of SRs. Epidemiological characteristics included, for example, the number of authors per review, country of corresponding author, and review ICD-10 categories. Descriptive characteristics of the assessed SRs included, for example, the use of data management software, the number of included studies, and the use of reporting guidelines. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist as a template , reporting characteristics were assessed for inclusion of items such as eligibility criterion, description of search strategy, data extraction, results, analysis, and source of funding.
All analyses are descriptive, with data summarized using frequency and percentage, or median and inter-quartile range (IQR) of SRs for both samples.
Electronic searching yielded a total of 389 unique records of which 57 were excluded at title and abstract screening. A total of 174 SRs were included in the CAM sample. Of the 174 CAM sample SRs evaluated, 43 were identified as reviews published in the Cochrane Library. As Cochrane reviews follow specialized, detailed and consistent methodology and reporting guidelines and as a result may differ in quality , . The CAM SRs sample was adjusted to exclude Cochrane Reviews in order to ensure comparability with the control sample. Results of a total of 131 CAM SRs are reported of which 6 were non-English language (Figure 2).
Electronic searching yielded a total of 1,537 possibly relevant citations for the control sample of which 174 reports were excluded during title and abstract screening. Of 1,363 SR reports reviewed at full text, 697 were excluded and the remaining 666 reports were eligible for inclusion. Of those eligible a random sample of 175 SR reports was included (Figure 2).
The median journal impact factor (2010) was lower for the CAM sample [median (IQR) 2.19 (1.50, 3.40)] across 93 journals compared to the control sample [median (IQR) 5.39 (3.40, 10.78)] across 61 journals. Overall, CAM SRs had fewer authors cited than SRs in the control sample, with 36% (47/131) of CAM reviews and 23% (41/175) of the control sample authored by 2–3 persons, compared to 42% (55/131) of CAM SRs and 54% (94/175) of control SRs with 4–6 authors. CAM reviews were more evenly distributed over corresponding authors’ country, with 29% (38/131) of authors from one of 17 other countries in contrast to, 29% (52/175) of control SRs whose corresponding authors were based in the United States. Corresponding authors with South Korean and Chinese affiliations differed between the CAM and control samples, with 10% (13/131) of reviews in the CAM sample with South Korean authors versus none of the control SRs, and 13% (17/131) Chinese corresponding authors in the CAM sample compared to 6% (11/175) in the control group.
The six most common ICD-10 categories for SRs were similar across both samples, however, there were notably fewer (0.76%, 1/131) CAM reviews focusing on pregnancy, child birth and purperium compared to the control sample (13.71%, 24/175). Almost all CAM SRs focused primarily on treatment (93.13%, 122/131), considerably more than the control sample (54.29%, 95/175). None of the CAM SRs focused on prevention, diagnosis or prognosis, while 7% (9/131) of reviews assessed either prevalence of use, education, or overall health, which we categorized as ‘other’ in our data extraction (Table 1).
Fewer CAM SRs were updates of original reviews (5.34%, 7/131) compared to control SRs (10.29%, 18/175). The median number of included studies was similar across both samples, as were the number of included participants. Likewise, the number of SRs considering cost-effectiveness analysis was comparable in the CAM and control samples [3% (4/131) and 2% (3/175), respectively].
The reported use of free and commercially available SR software in both samples was low, less than 3% (4/131) for CAM reviews and less than 5% (8/175) of control reviews. Fewer CAM SRs reported using any reporting guidelines (23.67%, 31/131) compared to the control sample SRs (50.86%). However, substitute use of reporting guidance, such as using a reporting guideline for RCTs (i.e. CONSORT ) instead of one for SRs (i.e. PRISMA , MOOSE ), was higher in the control sample of SRs (18.86%, 33/175) versus the CAM SRs, where no misuse or substitution was identified. Meta-analysis was less frequently performed in CAM reviews, with pooled effects reported in less than 50% (65/131) of CAM SRs versus 75% (132/175) of control SRs. The median number of meta-analyses per review were similar for the CAM sample [median (IQR), 4 (3, 9)] and the control sample [median (IQR), 7 (4, 14)]. However, there were far more CAM reviews compared to control reviews reporting only 2 studies in their largest meta-analysis ([11% (7/131)] versus) <1% (1/175), respectively]). Random effects models were more frequently used across all reviews for meta-analyses, while 19% (12/131) of CAM SRs and 17% (22/175) of control SRs reported using both random and fixed effects models. Almost 10% (6/131) of CAM reviews and 5% (7/175) of control reviews did not report which model(s) used when running meta-analyses (Table 2).
Over 20% (28/131) of CAM SRs and 16% (28/175) of control SRs did not use the terms “systematic review” or “meta-analysis” the title of the review report (Table 3). Fewer CAM reviews were described as a “meta-analysis” in the title and abstract [44% (57/131) versus 60% (105/175) of control SRs]. Of those described as a meta-analysis in the title, 22.81% (30/131) of CAM SRs versus 1% (2/175) of the control SRs did not report pooled estimates of effect.
Less than 5% of all SRs reported public availability of a review protocol [2.29% (3/131) of CAM SRs versus 4.70% (8/175) of control SRs]. CAM SRs were more likely than control SRs to restrict eligibility of primary studies to RCTs [64% (84/131) versus 33% (58/175), respectively], when adjusting for primary review focus, treatment-only control 44.21% (42/95) of SRs were restricted to include RCTs only. Less than 20% of reviews in both samples (15% of CAM SRs and 19% of control SRs) considered both published and unpublished literature for inclusion. CAM reviews were less likely to restrict eligibility by language of publication, with 22% (28/131) restricted to English versus 45% (79/175) of the control sample reviews. The median number of electronic databases searched for CAM reviews was higher than that for control reviews [median (IQR), 6 (4, 7) compared to 3 (2, 5) respectively]. CAM reviews were less likely than control reviews to search either MEDLINE® or EMBASE® [68% (89/131) versus 98% (172/175), respectively], or to report hand-searching for literature (66% of CAM reviews versus 88%, respectively). However, CAM reviews were more likely to completely report dates of searching [86% (113/131) versus 35% (61/175) of control reviews].
CAM reviews were more likely to have specified a primary outcome [57% (75/131) compared to 21% (37/175) control], and slightly more likely to have described the methods used in screening studies for inclusion [57% (75/131) of CAM SRs compared to 21% (37/175) of control sample SRs]. Almost one-third of both CAM and control SRs [31% (41/131) versus 29% (50/175), respectively] did not report how data extraction was carried out.
The risk of bias assessment within included studies varied considerably across the samples. For example, although 28% (37/131) of CAM SRs and 17% (30/175) of control SRs used the Cochrane Risk of Bias Tool , 83% of CAM reviews used a tool identified as relatively less frequently used  (e.g., MINORS , Downs and Black , Zaza ). Self-developed tools were used in 4% (5/131) of CAM reviews and 11% (19/175) of control SRs. Of the CAM reviews, 19/131 reviews used more than one tool (Table 3).
More than half of all reviews included a PRISMA-like flow diagram [50% (66/131) of CAM SRs and 55% (96/175) of control SRs]. Heterogeneity or ‘consistency’ amongst included studies was formally assessed frequently across both groups. The CAM sample contained less than 5% (6/131) of SRs reporting an assessment for publication bias in comparison to a 46% (80/175) reporting rate in the control sample. The most common means of assessing publication bias was by funnel plot. Over 80% of reviews in both samples discussed the limitations of their review (82% CAM SRs and 90% control SRs). Source of funding was frequently and consistently underreported, and less than 5% of reviews across samples were reported as being funded by for-profit organisations (0% CAM SRs versus 3% control SRs) (Table 3).
Systematic reviews (SRs) are being published in abundance and, as such, their reporting characteristics and methodological rigor must be assessed to ensure that research produced is of the highest standard. Research in the field of CAM is considerable with 43,312 trials listed in the Cochrane CAM field trials database, and approximately 10% of Cochrane reviews are CAM-related, as of October 2012 . Thus, it is important to independently assess the quality of reporting of CAM reviews and useful to draw comparisons to a more general sample of SRs to assess the strengths and weaknesses of both groups. Many findings of this evaluation are notable and suggest that there are some considerable differences between how CAM and control SRs are conducted and subsequently reported. There is no evident consistency in the completeness of reporting or quality of conduct between samples. As a result, findings should be considered on an item-by-item basis.
Many similarities in the frequency of adequate reporting between CAM and control SRs were observed. The number of reported updates was low across both samples, perhaps due to limited funding availability or other barriers . Many reviews from both samples did not report the use of reporting guidelines to assist in report writing. This may imply that reporting guidelines were not followed or that guideline use was simply not reported. Selective reporting was not assessed sufficiently across both samples, perhaps due to a lack of available guidance for dealing with this potential bias. In analyses, a number of SRs across groups reported running both fixed and random effects models; again the guidance in this regard is not explicit about the appropriateness of such a measure. However, it is our recommendation that the model used should always be pre-specified and reported in a publicly available review protocol. Finally, source of funding was frequently and consistently underreported in both samples, possibly indicating an area of reporting that is in need of improvement across all SR research.
There were a number of discrepancies between both groups. CAM SRs were found to be published in journals with a lower median impact factor compared to the control sample. Also, the focus of CAM reviews was almost exclusively for evaluating treatments, whereas 15% of control reviews evaluated preventive therapies. This is not unexpected because preventative therapies typically require longer term and more expensive trials, there are limited resources to conduct such trials of CAM interventions which are typically not industry funded. In 68% of CAM reviews and 98% of control reviews, either MEDLINE or EMBASE, or both were searched. This is an interesting result, in that many reviewers consider it standard practice to search both MEDLINE and EMBASE. Therefore, it is surprising that 32% of CAM SRs did not search either database, regardless of the diverse nature of review topics that often require searching of less well known databases as well. Despite MEDLINE® and EMBASE® being searched less frequently in CAM reviews, on average, CAM reviews did search more databases; this is consistent with previous findings  and with the language-based hypothesis above. Risk of bias assessment within included studies varied considerably across the samples; 28% of CAM SRs and 17% of control SRs used the Cochrane Risk of Bias Tool . These findings are consistent with other research . Moreover, 83% of CAM reviews used less prominent tools and self-developed tools were used in 4% of CAM reviews and 11% of control SRs. There are a substantial number of methods used to assess the quality of primary studies in both samples of SRs. This is consistent with previous research which reported of 177 reviews, 38% defined a method of quality assessment, within which 74 different methodological items and 26 different scales were identified .
Assessment of publication bias was reported in 46% of the control sample reviews, compared to less than 5% of SRs in the CAM sample. Accepted methods for assessing publication bias recommend the inclusion of ten or more studies .Therefore, the less frequent assessment in CAM reviews could be explained by the 25% lower rate of less formal meta-analyses compared to control SRs, or potentially due to the inclusion of fewer primary studies in CAM reviews.
In considering our findings in comparison to those of the Moher 2007 paper assessing 300 SRs (we refer to this as the ‘2004 sample’), we interpret these comparisons cautiously as there are some differences in sampling methods, most notably in the inclusion of Cochrane reviews in the 2004 sample. Similar to the comparison CAM and control samples in this evaluation, there are similarities and differences are between the 2004 sample and the current samples. Similarities include both the control sample and the 2004 sample having comparable frequencies with databases searched per review [median (IQR), 3 (2, 5)]. While over 65% of both CAM and control SRs used the term “systematic review” or “meta-analysis” in the title, this was the case for only 50% of the 2004 sample. The percentage of CAM reviews with reported primary outcomes was similar to that of the 2004 sample.
Considerable differences were noted in the frequency of reviews conducting cost-effectiveness analyses, with both the CAM and control samples having relatively low numbers compared to the 2004 sample. This is potentially due to the 2004 sample including more health technology assessments in which more cost-effectiveness analyses are generally conducted. The 2004 sample of reviews saw assessment of publication bias reported in 31% of review, while this item was reported more frequently in the control sample and less frequently in the CAM sample. The finding that less than 5% of all SRs reported public availability of a review protocol differs substantially from the 46% seen in the 2004 sample. This most likely reflects the impact of the large number of Cochrane reviews in the 2004 sample, which all require a published protocol. In the 2004 sample, 53.7% of reviews conducted meta-analysis; this number has increased to 75% in the control sample, whereas the findings for CAM remained consistent with the 2004 sample. Moreover, both current samples saw a smaller percentage of updated reviews compared to the 2004 sample.
Both the CAM and control samples had a higher number of multi-authored reports compared to the 2004 sample of reviews. We consider this to be positive, as participation of more authors may contribute more well-rounded insight into the conduct and reporting of research. The increase in use of flow diagrams in reports, the extent of consistency amongst included studies, and the completeness of reporting of review limitations have also increased in the collective 2011 sample, compared to the 2004 sample. The considerably higher frequency of reporting of a flow diagram in 2011 may suggest that the QUality Of Reports Of Meta-analyses of randomised controlled trials (QUOROM  and subsequent PRISMA  reporting guidelines are having an impact on the reporting of SRs.
There are some limitations to this evaluation. In particular, the magnitude of differences between the CAM and control SRs may be due to discrepancies in how the groups were sampled. Both 2011 strategies were modelled from the 2004 search strategy  however, some temporal variation could be present due to the time periods in which the samples were taken (2011 versus 2004). Further, the 2004 sample was restricted to English-language publications only, while we did not restrict the CAM sample to English-language reviews. Due to the size of the 2011 control SR sample yield, we restricted the search to core clinical journals. Applying this filter reduced the screening burden considerably (∼20,000 records) by focussing on journals which are deemed by the National Library of Medicine to be of immediate interest to practicing clinicians. There is no evidence to suggest that core clinical journals systematically differ from all other journals however, this may have had a minor influence on the results of this study. The evolution of the PRISMA Statement in 2009 , used to define a SR in this research, may have potentially resulted in a different population of eligible SRs in comparison to the 2004 sample, possibly affecting the comparison of frequencies between groups. The extent to which these selection criteria affect the results is unknown.
In conclusion, the quality of reporting is variable between CAM and control SRs, and in comparison to the 2004 sample. The two 2011 samples exhibited different strengths and weaknesses, but no discernible patterns emerged. This could be explained by the possibility that, as a whole, CAM researchers may operate somewhat differently than the general research community, with different priorities and ways of conducting and reporting research, while still adhering to some of the basic principles of good reporting. The inconsistencies raise questions regarding the appropriateness and extent to which all reviews should aspire to report SR findings using the same systematic approach, or whether more specific reporting guidelines may be needed for specific research areas for SRs, such as CAM. Examples from other reporting guidelines, such as the CONSORT Statement , , suggest that extensions to particular subgroups are both feasible and warranted.
In some instances, there were similarities across one or more items between the two groups and/or between the 2011 and 2004 samples. This may indicate circumstances in which there is a need for continued improvements regarding particular aspects of reporting across all SR research. Educators and researchers focused on improving the quality of reporting of SRs may be able to use our finding to improve teaching, future research and the development and improvement of tools in this area. These findings may point to a need for more awareness and training on particular aspects of reporting quality that may be less of a priority among researchers in particular areas of research, or across all SRs. Future SRs would benefit from utilizing the PRISMA Statement , as it provides a useful and comprehensive tool for ensuring the quality of reporting when drafting SR reports.
Click here for additional data file (pone.0053536.s001.rtf)
We would like to thank Dr. Andrea Tricco and Ms. Jennifer Tetzlaff for providing the standardized data extraction forms. We would like to thank Ms’. Sophia Tsouros, Mary Gauthier and Misty Pratt for their substantial contribution to screening and data extraction. We would also like to thank Ms. Becky Skidmore and Mr. Raymond Daniel for their support with search development and article acquisition. Finally, we would like to thank Drs. Taixiang Wu, Anette Bluemle, Jannie Hedegaard, Gabriela Lewin, Karla Soares-Weiser and Tinghua Zhang for their assistance in screening and extracting data from non-English language articles.
|1.||Bastian H,, Glasziou P,, Chalmers I, (Year: 2010) Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?PLoS Med7: e100032620877712|
|2.||Board on Health Services (2011) Finding What Works in Health Care: Standards for Systematic Reviews. Available: http://www.iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews.aspx Accessed 2012 Jul.|
|3.||Moher D,, Liberati A,, Tetzlaff J,, Altman DG, (Year: 2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med6: e100009719621072|
|4.||Moher D,, Tetzlaff J,, Tricco AC,, Sampson M,, Altman DG, (Year: 2007) Epidemiology and reporting characteristics of systematic reviews. PLoS Med4: e7817388659|
|5.||Barnes PM, Bloom B, Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 1–23.|
|6.||Harris P,, Rees R, (Year: 2000) The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med8: 88–9610859601|
|7.||Harris P, (Year: 2000) Difficulties of conducting systematic reviews of survey studies. Complement Ther Med8: 28811098211|
|8.||Wieland LS,, Manheimer E,, Berman BM, (Year: 2011) Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med17: 50–5921717826|
|9.||U.S National Library of MedicineAbridged Index Medicus (AIM or “Core Clinical”) Journal Titles. Available: http://www.nlm.nih.gov/bsd/aim.html Accessed 2012 Sep 19.|
|10.||Higgins JPT, Green S (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available: http://www.cochrane-handbook.org Accessed 2012 Jul 18.|
|11.||Liberati A,, Altman DG,, Tetzlaff J,, Mulrow C,, Gotzsche PC,, et al. (Year: 2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med6: e100010019621070|
|12.||(2012) The Canadian Agency for Drugs and Technologies in Health Website. Available: www cadth ca. Accessed 2012 Oct 19.|
|13.||(2010) DistillerSR. Evidence Partners, Ottawa, ON, Canada. Available: www.systematic-review.net|
|14.||(2011) SAS Software, Version 9.1 Copyright©. SAS Institute Inc Cary, NC, USA.|
|15.||Moseley AM,, Elkins MR,, Herbert RD,, Maher CG,, Sherrington C, (Year: 2009) Cochrane reviews used more rigorous methods than non-Cochrane reviews: survey of systematic reviews in physiotherapy. J Clin Epidemiol62: 1021–103019282144|
|16.||Tricco AC,, Tetzlaff J,, Pham B,, Brehaut J,, Moher D, (Year: 2009) Non-Cochrane vs. Cochrane reviews were twice as likely to have positive conclusion statements: cross-sectional study. J Clin Epidemiol62: 380–38619128940|
|17.||Schulz KF,, Altman DG,, Moher D, (Year: 2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ340: c33220332509|
|18.||Stroup DF,, Berlin JA,, Morton SC,, Olkin I,, Williamson GD,, et al. (Year: 2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA283: 2008–201210789670|
|19.||Higgins JPT, Altman DG, Sterne JAC (editors) (Year: 2011) Assessing risk of bias in included studies. In: http:,, handbook.cochrane.org/. , editors. Cochrane Handbook for Systematic Reviews of Interventions : Cochrane Book Series. Accessed 18 July2012: 187–241|
|20.||Dechartres A,, Charles P,, Hopewell S,, Ravaud P,, Altman DG, (Year: 2011) Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed. J Clin Epidemiol64: 136–14420705426|
|21.||Slim K,, Nini E,, Forestier D,, Kwiatkowski F,, Panis Y,, et al. (Year: 2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg73: 712–71612956787|
|22.||Downs SH,, Black N, (Year: 1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health52: 377–3849764259|
|23.||Zaza S,, Carande-Kulis VG,, Sleet DA,, Sosin DM,, Elder RW,, et al. (Year: 2001) Methods for conducting systematic reviews of the evidence of effectiveness and economic efficiency of interventions to reduce injuries to motor vehicle occupants. Am J Prev Med21: 23–3011691559|
|24.||(2012) Cochrane Central Register of Controlled Trials (CENTRAL). The Cochrane Library Issue 9. Accessed 10 October 2012.|
|25.||Garritty C,, Tsertsvadze A,, Tricco AC,, Sampson M,, Moher D, (Year: 2010) Updating systematic reviews: an international survey. PLoS One5: e991420376338|
|26.||Egger M,, Juni P,, Bartlett C,, Holenstein F,, Sterne J, (Year: 2003) How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess7: 1–7612583822|
|27.||Hartling L, Schellenberg ES, Shulhan J, Dryden DM (2012) Approaches to risk of bias assessments in non-Cochrane reviews. Poster presentation at the 20th Cochrane Colloquium, Auckland, New Zealand.|
|28.||Sterne JA,, Sutton AJ,, Ioannidis JP,, Terrin N,, Jones DR,, et al. (Year: 2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ343: d400221784880|
|29.||Moher D,, Cook DJ,, Eastwood S,, Olkin I,, Rennie D,, et al. (Year: 1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet354: 1896–190010584742|
|30.||MacPherson H,, Altman DG,, Hammerschlag R,, Youping L,, Taixiang W,, et al. (Year: 2010) Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT statement. J Evid Based Med3: 140–15521349059|
|31.||Boutron I,, Moher D,, Altman DG,, Schulz KF,, Ravaud P, (Year: 2008) Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med148: W60–W6618283201|
|32.||(2008) RevMan 2008 The Cochrane Collaboration (2008) Review Manager (RevMan). 5 0 Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration.|
|33.||(2012) ENDNOTE citation software. Thomson Reuters ISI.|
|34.||Brozek J, Oxman A, Schünemann H (2008) GRADEpro. Version 3.2 for Windows.|
|35.||(2008) Refworks-COS. Available: www refworks com. Accessed 2012 Oct 19.|
|36.||von EE,, Altman DG,, Egger M,, Pocock SJ,, Gotzsche PC,, et al. (Year: 2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol61: 344–34918313558|
|37.||Guyatt GH,, Oxman AD,, Schunemann HJ,, Tugwell P,, Knottnerus A, (Year: 2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol64: 380–38221185693|
|38.||Phillips B, Ball C, Sackett D, Badenoch D, Straus S, et al. . (2009) Oxford Centre for evidence-based medicine online guidelines. Availablet: http://www cebm net/index aspx?o = 1001. Accessed 2012 Oct 19.|
|39.||National Institute for Health and Clinical Excellence: Guidance (2003) London: National Institute for Health and Clinical Excellence (UK) Available: http://www.ncbi.nlm.nih.gov/books/NBK11822/Accessed 2012 Oct.|
|40.||Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys Ther81: 1641–1674|
|41.||Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, et al. . (2008) Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions.|
|42.||Jadad AR,, Moore RA,, Carroll D,, Jenkinson C,, Reynolds DJ,, et al. (Year: 1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials17: 1–128721797|
|43.||Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al. . (2008) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri ca/programs/clinical_epidemiology/oxford asp. Accessed Oct 2012.|
|44.||Egger M,, Davey SG,, Schneider M,, Minder C, (Year: 1997) Bias in meta-analysis detected by a simple, graphical test. BMJ315: 629–6349310563|
|45.||Cox E,, Martin BC,, Van ST,, Garbe E,, Siebert U,, et al. (Year: 2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report–Part II. Value Health12: 1053–106119744292|
|46.||Verhagen AP,, de Vet HC,, de Bie RA,, Kessels AG,, Boers M,, et al. (Year: 1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol51: 1235–124110086815|
|47.||Harris RP,, Helfand M,, Woolf SH,, Lohr KN,, Mulrow CD,, et al. (Year: 2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med20: 21–3511306229|
|48.||Cho MK,, Bero LA, (Year: 1994) Instruments for assessing the quality of drug studies published in the medical literature. JAMA272: 101–1048015115|
|49.||Sauerland S,, Angrisani L,, Belachew M,, Chevallier JM,, Favretti F,, et al. (Year: 2005) Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc19: 200–22115580436|
|50.||(2012) American Academy of Neurology guidelines. Available: www aan com. Accessed 2012 Oct.|
|51.||de Morton NA, (Year: 2009) The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Aust J Physiother55: 129–13319463084|
|52.||Tong A,, Sainsbury P,, Craig J, (Year: 2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care19: 349–35717872937|
|53.||West S, King V, Carey TS, Lohr KN, McKoy N, et al. . (2002) Systems to rate the strength of scientific evidence. Evid Rep Technol Assess (Summ) 1–11.|
|54.||Schulz KF,, Chalmers I,, Hayes RJ,, Altman DG, (Year: 1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA273: 408–4127823387|
|55.||Phillips B, Ball C, Sackett D, Badenoch D, Straus S, et al. . (2009) Oxford Centre for Evidence-based Medicine - Levels of Evidence. Centre for Evidence Based Medicine Avaialble: http://www.cebm.net/index.aspx?o=1025 Accessed 2012 Dec.|
|56.||Santaguida P, Raina P, Ismaila A (2012) The development of the McHarm quality assessment scale for adverse events. Available: http://hiru.mcmaster ca/epc/mcharm pdf. Accessed 2012 Dec.|
|57.||Oxman AD,, Guyatt GH, (Year: 1991) Validation of an index of the quality of review articles. J Clin Epidemiol44: 1271–12781834807|
|58.||Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J (2001) Undertaking systematic reviews of research on effectiveness: CRD’s guidance for carrying out or commissioning reviews. NHS Centre for Reviews and Dissemination.|
|59.||(2012) Critical Appraisal Skills Programme: Making sense of evidence. Available: http://www casp-uk net/. Accessed 2012 Oct 18.|
|60.||Harbour R,, Miller J, (Year: 2001) A new system for grading recommendations in evidence based guidelines. BMJ323: 334–33611498496|
|61.||Stetler CB,, Morsi D,, Rucki S,, Broughton S,, Corrigan B,, et al. (Year: 1998) Utilization-focused integrative reviews in a nursing service. Appl Nurs Res11: 195–2069852663|
|62.||van TM,, Furlan A,, Bombardier C,, Bouter L, (Year: 2003) Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine (Phila Pa 1976 )28: 1290–129912811274|
|63.||Debachere MC, (Year: 1995) Problems in obtaining grey literature. IFLA Journal21: 94–98|
[Figure ID: pone-0053536-g001]
Figure 1 Defining a ‘systematic review’.
[Figure ID: pone-0053536-g002]
Figure 2 Flow diagram of included systematic reviews.
Table 1 Epidemiology of Systematic reviews.
|CAM Group||Control Group||Moher 2007 |
|Category||Characteristics||n (%), N = 131||n (%), N1 = 175||n (%), N = 300|
|Total Number of Journals||93||61||132|
|2010 Journal Impact Factor, Median (IQR)||2.19 (1.50, 3.40)||5.39 (3.40, 10.78)|
|Number of authors||1||6 (4.58)||1 (0.57)||24 (8.0)|
|2–3||47 (35.88)||41 (23.43)||125 (41.7)|
|4–6||55 (41.99)||94 (53.71)||128 (42.7)|
|≥7||23 (17.58)||39 (22.29)||23 (7.7)|
|Country of Corresponding Author||Australia||9 (6.87)||6 (3.43)||31 (10.30)|
|Austria||1 (0.76)||3 (1.71)|
|Canada||11 (8.40)||30 (17.14)||28 (9.3)|
|China||17 (12.80)||10 (5.71)|
|Germany||5 (3.82)||5 (2.86)||10 (3.3)|
|South Korea||13 (9.92)||0 (0.00)|
|The Netherlands||6 (4.58)||11 (6.29)||17 (5.7)|
|UK||19 (14.50)||27 (15.43)||76 (25.3)|
|US||21 (16.03)||52 (29.14)||68 (22.7)|
|Othera||38 (29.01)||27 (15.43)||60 (20.0)|
|Common ICD-10 Categories||Diseases of the circulatory system||15 (11.45)||30 (17.14)||33 (11.0)|
|Diseases of the genitourinary system||8 (6.11)||8 (4.57)|
|Diseases of the musculoskeletal system and connective tissue||31 (23.66)||18 (10.29)|
|Malignant neoplasms||8 (6.11)||14 (8.00)||22 (7.3)|
|Mental and behavioural disorders||16 (12.21)||19 (10.86)||40 (13.3)|
|Pregnancy, childbirth and the puerperium||1 (0.76)||24 (13.71)||21 (7.0)|
|Primary Focus||Treatment||122 (93.13)||95 (54.29)||21.3 (71.0)|
|Prevention||0 (0.0)||27 (15.43)|
|Prognosis||0 (0.0)||24 (13.71)||23 (7.7)|
|Diagnosis||0 (0.0)||13 (7.43)|
|Otherb||9 (6.87)||16 (9.14)||46 (15.3)|
aMoher 2007 : 30 countries <10 reviews/country. Control Group: India, Norway, Sweden, Belgium, Brazil, Denmark, Greece, Israel, Italy, Poland, Singapore, Spain, Switzerland. CAM Group: Japan, New Zealand, Thailand, Belgium, Chile, Denmark, Hong Kong, Ireland, Italy, Malaysia, Nigeria, Oman, Peru, Saudi Arabia, South Africa, Spain, Taiwan.
bMethodological, educational, prevalence of use, overall health effects and mindfulness.
Table 2 Descriptive Characteristics of systematic reviews.
|CAM Group||Control Group||Moher 2007 |
|Category||Characteristics||n (%), N = 131||n (%), N1 = 175||n (%), N = 300|
|Type of Interventionsc||Pharmacological||34 (29.60)||57 (32.57)||142 (47.3)|
|Non-Pharmacological||94 (71.75)||61 (34.95)||113 (37.7)|
|No Intervention||3 (2.29)||57 (32.57)||42 (14.0)|
|Update of a previous review||Updated||7 (5.34)||18 (10.29)||53 (17.7)|
|Number of included studies, Median (IQR)||14 (8, 28)||18 (10.25, 33.75)||16 (7, 30)|
|Number of participants, Median (IQR)||1013 (475.25, 2033.75)||2815 (1111, 8460)a||1,112 (322–3,750)|
|Economics considered||Cost-effectiveness analysis conducted||4 (3.05)||3 (1.71)||61 (24.0)|
|No||124 (94.65)||172 (98.29)||193 (76.0)|
|Cochrane Review||Yes (includes co-publications)||3 (2.29)||2 (1.16)||–|
|Data Management Software||Usedd||4 (3.05)||8 (4.57)||–|
|Not used/Not reported||127 (96.94)||167 (95.43)||–|
|Reported Use of Reporting Guidelines||None||100 (76.33)||86 (49.14)||–|
|PRISMA ||3 (2.29)||21 (12.00)||–|
|QUOROM ||7 (5.34)||13 (7.43)||–|
|MOOSE ||0 (0.0)||16 (9.14)||–|
|Substitute usee||0 (0.0)||33 (18.86)||–|
|Otherf||21 (16.03)||6 (3.43)||–|
|Quantitative Analysis||65 (49.61)||132 (75.43)||161 (53.7)|
|Number of pooled effectsg, Median (IQR)||4 (3, 9)||7 (4, 14)||–|
|Number of studies in largest meta–analysis||2||7 (10.93)||1 (0.76)||–|
|3–5||20 (31.25)||27 (20.45)||–|
|6–8||14 (21.87)||22 (16.67)||–|
|9–11||8 (12.50)||20 (15.15)||–|
|12–25||9 (14.06)||41 (31.06)||–|
|26–50||4 (3.05)||14 (10.61)||–|
|50–100||1 (0.76)||3 (2.27)||–|
|100+||0 (0.0)||1 (0.76)||–|
|Unit of measure for the primary outcome(s)||Difference in Means||15 (23.43)||30 (22.73)||–|
|Standardised Mean Difference||17 (26.56)||14 (10.61)||–|
|Risk Ratio||18 (28.12)||29 (21.97)||–|
|Odds Ratio||7 (10.93)||39 (29.55)||–|
|Risk Difference||2 (3.15)||2 (1.52)||–|
|Hazard Ratio||0 (0.0)||12 (9.10)||–|
|Likelihood Ratios||0 (0.0)||10 (7.58)||–|
|PPV, NPV||0 (0.0)||4 (3.03)||–|
|Unclear||2 (3.15)||0 (0.00)||–|
|Model applied||Random Effects||37 (57.81)||67 (50.76)||–|
|Fixed Effects||9 (14.06)||17 (12.88)||–|
|Both||12 (18.75)||22 (16.67)||–|
|Not Reported||6 (9.37)||7 (5.30)||–|
cIt should be noted that where CAM reviews are pharmacological pertains to reviews which include a CAM and conventional intervention.
fSpecifically referred to as reporting guidance, Cochrane Handbook or named Cochrane review group , STRICTA , GRADE , Centre for evidence-based medicine guidelines at the University of Oxford , NICE Guidance , Cooper’s 5-stage model, Guidelines from the Philadelphia panel classification system , AHRQ guidance .
gSynthesis had to include more than one study and estimates reported both in the text and as a figure were only included in the count once.
Table 3 Reporting Characteristics of systematic reviews.
|Category||Subcategory||Group||CAM Group n (%), N = 131||Control Group n (%), N = 175||Moher 2007  N (%), N = 300|
|Use of term “systematic review” in title||97 (74.04)||116 (66.29)||150 (50.0)h|
|Use of term “meta-analysis in title”||57 (43.51)||105 (60.00)||–|
|Neither term reported||28 (21.34)||28 (16.00)||150 (50.0)|
|Protocol Mentioned||Total Reported||7 (5.34)||25 (14.29)||139 (46.3)|
|Publically Available||3 (2.29)||8 (4.7)||–|
|Eligibility Criteria||Subject to study design||No restrictions||11 (0.76)||50 (28.57)||–|
|RCT||84 (64.12)||58 (33.14)||176 (60.1)|
|RCT and Others||20(15.26)||39 (22.29)||–|
|Observational Case Controlled||0 (0.00)||10 (5.71)||21 (7.2)|
|Observational||0 (0.00)||12 (6.86)||14 (4.8)|
|Prospective studies||5 (3.81)||5 (2.86)||–|
|Other/Unclear||4 (3.05)||1 (0.57)||89 (29.67)|
|Subject to publication status||Yes, published and unpublished||20 (15.26)||33 (18.86)||123 (41.0)|
|Yes, unpublished only||0 (0.00)||0 (0.00)||0 (0.00)|
|Yes, published only||52 (39.69)||69 (39.43)||68 (22.7)|
|Not reported/Unclear||55 (41.98)||73 (41.71)||109 (36.3)|
|Subject to language of publication||English Only||28 (21.37)||79 (45.14)||49 (16.3)|
|Specified mix||20 (15.26)||24 (13.71)||6 (2.0)|
|No restrictions||64 (48.85)||63 (36.00)||110 (36.7)|
|Not reported||15 (11.45)||9 (5.14)||134 (44.7)|
|Search||Number of databases searched, Median (IQR)||6 (4, 7)||3 (2, 5)||3 (2, 5)|
|Medline or EMBASE searched||89 (67.93)||172 (98.29)||–|
|Non-electronic methods of searching reported||87 (66.41)||154 (88.00)||–|
|reporting of search years of coverage||Yes||113 (86.25)||61 (34.86)||208 (69.3)|
|Partially reported||13 (9.92)||110 (62.86)||49 (49 (16.3)|
|No||5 (3.81)||4 (2.29)||43 (14.33)|
|Search terms reported||No search terms reported||12 (9.16)||13 (7.42)||37 (12.3)|
|Full search strategy as appendix or link||37 (28.24)||23 (13.14)||132 (44.00)|
|Keywords, MeSH index terms and/or free text reported and/or topics||82 (62.59)||119 (68.00)||128 (42.67)|
|Data Extraction||Specified one or more primary outcome||75 (57.25)||37 (21.14)||143 (51.1)|
|Methods of screening||Two reviewers in duplicate||55 (41.98)||92 (52.57)||–|
|By two of many||6 (4.58)||8 (4.57)||–|
|One reviewer only||4 (3.05)||8 (4.57)||–|
|Not reported||63 (48.09)||67 (38.29)||–|
|Methods of data extraction||Two reviewers in duplicatei||79 (60.30)||100 (57.14)||–|
|By two of many||5 (3.81)||14 (8.00)||–|
|Sample verification||2 (1.52)||6 (3.43)||–|
|One reviewer only||4 (3.05)||5 (2.86)||–|
|Not reported||41 (31.29)||50 (28.57)||–|
|Means of quality assessment||Risk of Bias Tool  or modification of||36 (27.48)||30 (17.14)||–|
|Jadad  or modification||41 (31.30)||24 (13.71)||–|
|Newcastle-Ottawa Scale ||1 (0.76)||10 (5.71)||–|
|Reporting Guideline||5 (3.81)||13 (7.43)||–|
|Did not report tool||5 (3.81)||9 (5.14)||–|
|Self-developed||5 (3.81)||19 (10.86)||–|
|Otherj||66 (50.38)||70 (40.00)||–|
|Results||A description of review flow||None||9 (6.87)||14 (8.00)||92 (30.7)|
|Partial, text and/or table||10 (7.63)||11 (6.29)||99 (33.0)|
|Complete, text and/or table||32 (24.43)||21 (12.00)||106 (35.3)|
|Complete, PRISMA flow like diagram||14 (10.69)||96 (54.86)||20 (6.7)|
|Complete, PRISMA flow like diagram and in text and/or table||66 (50.38)||35 (20.00)||–|
|Reasons for exclusion||Fully reported||28 (21.37)||139 (79.43)||144 (48.0)|
|Partially reported||5 (3.81)||16 (9.14)||119 (39.7)|
|None||8 (6.10)||20 (11.42)||50 (16.7)|
|Grey literaturek included||29 (22.13)||37 (21.14)||132 (44.0)|
|Consistency||Formally assessed||59 (90.76)||117 (66.86)||147 (49.0)|
|Qualitatively assessed||1 (0.76)||7 (4.00)||51 (17.0)|
|Not assessed/Not reported||5 (7.69)||51 (29.14)||102 (34.0)|
|Common methods for assessing consistency||I2||50 (38.16)||95 (71.97)||–|
|Cochrane Q/Chi2l||32 (24.42)||32 (24.24)||–|
|Visual Inspection||1 (0.78)||2 (1.51)||–|
|Tau2||13 (9.92)||1 (0.76)||–|
|L’Abbe Plot||0 (0.00)||2 (1.51)||–|
|Selective reporting was explicitly assessed||21 (16.03)||43 (24.57)||–|
|Assessment of publication bias reported||6 (4.58)||80 (45.71)||92 (31.3)|
|Common methods for assessing publication bias||Funnel Plot||2 (1.52)||79 (45.14)||–|
|Egger’s Test||1 (0.76)||7 (4.00)||–|
|Regression||1 (0.76)||35 (20.00)||–|
|Begg Test||1 (0.76)||3 (1.71)||–|
|Trim and Fill||0 (0.0)||11 (6.29)||–|
|Impact of assessment discussed in results||28 (23.14)||81 (46.29)||–|
|Discussion||Limitations discussed||107 (81.67)||157 (89.71)||–|
|Other||Source of Funding||Non-Profit||27 (20.61)||63 (36.00)||144 (48.0)|
|For profit||0 (0.0)||6 (3.43)||7 (2.3)|
|Author specified no funding||46 (35.11)||28 (16.00)||3 (1.0)|
|Mixed||1 (0.76)||0 (0.00)||19 (6.3)|
|Not Reported||36 (27.48)||78 (44.57)||127 (42.4)|
hReported as either “systematic review” or “meta-analysis”.
iIncludes 100% verification.
jControl Group: GRADE ; AHRQ Guidance ; Egger’s tool ; Downs and Black ; Zaza et al. ; publication bias only assessed; International Society of Pharmacoeconomics and Outcomes Research ; The Delphi list ; US Preventative Services Task Force criteria ; Cho and Bero ; Sauerland ; America academy of neurology ; PEDro ; COREQ ; West ; Schulz’s Allocation concealment ; outcome reporting bias only; Centre of evidence-based medicine at the University of Oxford ; MINORS ; DTA assessment; “assessed based on study design”; labelled sensitivity analysis as quality assessment; adjusted analysis by characteristics calling it quality assessment; CAM Group: GRADE ; NICE ; EPC based ; Downs and Black ; Delphi list ; PEDro ; Allocation concealment ; Centre of Evidence-Based Medicine at the University of Oxford ; McMaster Quality Assessment Scale of Harms (McHarm) ; Oxman and Guyatt ; Centre for reviews and dissemination ; MINORS ; CASP ; Scottish Intercollegiate Guidelines Network ; Stetler’s Evidence Ranking system ; Tulder Score ; MINORS ; Wilson and Lawrence Scores; RAC; Ostello.
kGray Literature searching refers to systematic review search methods to identify primary studies which are not identified via standard searching methods .
lIndependent of I2.
Previous Document: Rabbit neonates and human adults perceive a blending 6-component odor mixture in a comparable manner...
Next Document: Synchrotron-generated microbeam sensorimotor cortex transections induce seizure control without disr...